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Key PointsClinicopathologic classification of focal cortical dysplasia (FCD) is challenging in everyday praxisDNA methylation distinguished between human FCD types Ia, IIa, and IIb; temporal lobe epilepsy; and nonepileptic controlsDNA methylation signatures may constitute a clinically useful molecular biomarker for FCD subtypes

1. INTRODUCTION {#epi14934-sec-0006}
===============

Focal cortical dysplasia (FCD) is a frequent pathoanatomic substrate of severe drug‐resistant focal epilepsy particularly in children.[1](#epi14934-bib-0001){ref-type="ref"} FCDs present with variable and difficult‐to‐classify histopathology patterns, including architectural, cytoarchitectural, and white matter abnormalities.[2](#epi14934-bib-0002){ref-type="ref"}, [3](#epi14934-bib-0003){ref-type="ref"} The International League Against Epilepsy (ILAE) proposed a clinicopathologic consensus classification based on microscopic review of surgical specimens.[4](#epi14934-bib-0004){ref-type="ref"}

The most frequent subtype is FCD II, which is localized mainly in the frontal lobe and often constrained to the depth of a sulcus.[5](#epi14934-bib-0005){ref-type="ref"} FCD type II was histopathologically characterized by megalocytic neurons (FCD type IIa) and "opalesque" balloon cells (FCD type IIb). Another FCD subtype has been described in young children with a multilobar onset in the posterior quadrant, daily seizures without focal neurologic deficits, intellectual disabilities, and drug‐resistance from onset.[6](#epi14934-bib-0006){ref-type="ref"} Their histopathologic hallmark is abundance of neuronal microcolumns across cortical layers 3‐5, that is, FCD Ia.[7](#epi14934-bib-0007){ref-type="ref"} Other FCD subtypes still lack comprehensive characterization of clinical phenotypes and often associate with a principal brain lesion, that is, FCD type IIIa in the temporolateral neocortex of patients with hippocampal sclerosis.

Continuous implementation of advanced diagnostic tools for presurgical evaluation has proven helpful in identifying FCD, for example, intracerebral electroencephalography (EEG) recording and high‐resolution magnetic resonance imaging (MRI).[8](#epi14934-bib-0008){ref-type="ref"} Nevertheless, detection of subtle FCD, diagnostic distinction of FCD subtypes, and large FCD patterns not compromising gross brain anatomy remain difficult in routine diagnostics. Prediction of postsurgical seizure freedom varies between FCD subtypes and is another issue demanding clarification.[6](#epi14934-bib-0006){ref-type="ref"}, [9](#epi14934-bib-0009){ref-type="ref"}, [10](#epi14934-bib-0010){ref-type="ref"} Thus, identification of pathogenetic signatures to develop useful diagnostic, predictive, or prognostic biomarkers and targeted therapies is an unmet clinical need.

The impact of integrating molecular genotypes with histopathologic phenotypes has recently been recognized by the World Health Organization (WHO) panel for the classification of brain tumors in 2016.[11](#epi14934-bib-0011){ref-type="ref"} Particularly, genomic DNA methylation classifiers have been identified as a valuable source in the decision making process for disease diagnosis, prognosis, and treatment.[12](#epi14934-bib-0012){ref-type="ref"} In this study, we examined whether genomic DNA methylation and gene expression could be also used to distinguish human FCD tissue.

2. METHODS {#epi14934-sec-0007}
==========

2.1. Patients included in the study {#epi14934-sec-0008}
-----------------------------------

Twenty‐six subjects from the European Epilepsy Brain Bank with available fresh‐frozen human brain samples and adjacent formalin‐fixed paraffin‐embedded (FFPE) tissue blocks were included in the present study (Figure [1](#epi14934-fig-0001){ref-type="fig"}A).[1](#epi14934-bib-0001){ref-type="ref"}, [13](#epi14934-bib-0013){ref-type="ref"} All patients were recruited between 2002 and 2014 and underwent extensive presurgical evaluation including video‐EEG monitoring, neuropsychological examination, and MRI (1.5 or 3 Tesla; Siemens). One patient received computerized tomography (CT) imaging only. In selected cases, PET and SPECT analysis were applied. En bloc resections were carried out depending on the presurgical characterization of the seizure focus. Resected tissue samples were sliced and alternating sections were either formalin‐fixed paraffin‐embedded or immediately frozen (in liquid nitrogen or over isopentane) and stored at −80°C until further use.[13](#epi14934-bib-0013){ref-type="ref"} FFPE‐ and cryosections from all surgical specimens underwent systematic evaluation by two experienced neuropathologists (I.B. and R.C.) with regard to the presence of seizure‐associated lesions and even representation of gray and white matter.[4](#epi14934-bib-0004){ref-type="ref"}, [14](#epi14934-bib-0014){ref-type="ref"} Histopathologically, 15 patients displayed FCD type Ia (microcolumns in Figure [1](#epi14934-fig-0001){ref-type="fig"}B; red arrow heads; n = 4; mean~Age~ ± standard error of mean (SEM): 5.3 ± 1.0), type IIa (dysmorphic neurons in Figure [1](#epi14934-fig-0001){ref-type="fig"}B; black arrows; n = 6; mean~Age~ ± SEM: 5.5 ± 1.4), or type IIb (dysmorphic neurons and balloon cells; black arrows and asterisks in Figure [1](#epi14934-fig-0001){ref-type="fig"}B; n = 5; mean~Age~ ± SEM: 10.6 ± 3.3). Five patients had temporal lobe epilepsy (TLE) associated with hippocampal sclerosis. In the present study, we used the resected temporal neocortex, which showed no histopathologic signatures of FCD (TLE; Figure [1](#epi14934-fig-0001){ref-type="fig"}B, upper right panel; mean~Age~ ± SEM: 30.60 ± 7.12 years). This group was used to control for aberrant methylation patterns that could have been induced by chronic seizures.[15](#epi14934-bib-0015){ref-type="ref"}, [16](#epi14934-bib-0016){ref-type="ref"} Autopsy cases and surgical samples from nonepilepsy patients served as controls (CTRL; n = 6; mean~Age~ ± SEM: 15.5 ± 2.0 years). Criteria for including these specimens as control tissue were age \<25 years, for autopsies a postmortem range \<24 hours, no prior history of seizures, and no signs of autolysis upon histopathologic brain examination. Patients with FCD type III (ie, FCD and an associated second lesion, eg, hippocampal sclerosis) were excluded from the study to avoid misinterpretation with regard to which lesion would be associated primarily with any molecular findings. Informed and written consent was obtained from all patients, their parents, or legal representatives if patients were underage. All studies were conducted in accordance with the Declaration of Helsinki and were approved by the local ethics committee of the Friedrich‐Alexander University Erlangen‐Nürnberg (FAU) Medical Faculty (Ref. No. 92_14 B).

![A, Clinical data summary. B, Histology overview shows NeuN immunohistochemical staining of representative neocortical specimens obtained from epilepsy patients with either focal cortical dysplasia (FCD) Ia, IIa, IIb, or temporal lobe epilepsy (TLE) (from left to right). Upon histopathologic examination, FCD subtype Ia was characterized by abundant microcolumnar organization (red arrow heads) and reduced cortical thickness. FCD type IIa and IIb showed no identifiable cortical layering except for layer 1. Hallmark of FCD II variants was the presence of dysmorphic neurons (black arrows), which presented with a significantly enlarged cell body and nucleus, malorientation, and cytoplasmic accumulation of neurofilament protein (SMI32). Histopathologic detection of Vimentin (VIM)--positive balloon cells further classified subtype IIb (2011 International League Against Epilepsy \[ILAE\] classification). FCD II cases showed varying degrees of pS6 immunoreactivity. In contrast to FCDs, temporal neocortex specimen obtained from patients with TLE and included in the present study showed no signs of cortical dyslamination or any cytomorphological changes similar to autopsy controls. C, Project design to investigate the association of FCD subtypes with genome‐wide DNA methylation and gene expression](EPI-60-1091-g001){#epi14934-fig-0001}

2.2. DNA methylation profiling {#epi14934-sec-0009}
------------------------------

For DNA methylation profiling, 500 ng of human DNA from each sample was fragmented to a median size of 200‐300 bp and subjected to methylated DNA capture according to the MethylMiner protocol (Invitrogen), enabling exclusive capture of methylated double‐stranded DNA. Fragmented and enriched DNA was eluted at high salt concentrations (2 mol/L NaCl). Ten nanograms of enriched DNA was used in library preparation using the NEB Next DNA Library Prep Reagent Set for Illumina (New England Biolabs). In parallel, 10 ng of sonicated DNA without enrichment also underwent library preparation to act as an input (background) control for each patient sample. Quality of sequencing libraries was assayed using the Shimadzu MultiNA capillary electrophoresis system (Shimadzu). Libraries were sequenced at a concentration of 13 pmol/L on the Illumina HiSeq2500 (Illumina) with a 100 bp single‐read length. Base calling was performed with RTA v1.18.61 software. Sequenced tags were aligned to the human reference genome hg19 using BWA‐ALN.[17](#epi14934-bib-0017){ref-type="ref"} Duplicate reads that aligned to the same location and strand in a given sample were removed using Samtools.[18](#epi14934-bib-0018){ref-type="ref"} Profiles of DNA methylation were compared between each sample and its respective input, using the MACS peak calling software.[19](#epi14934-bib-0019){ref-type="ref"} Identified peaks that occurred in at least two samples were used for further analysis. The numbers of read tags aligning to each region were extracted using featureCounts[20](#epi14934-bib-0020){ref-type="ref"} producing a matrix of counts (tags per region per sample). Genes with less than 100 sequence reads across all samples were removed from further analysis. All external data sources used for methylation analysis are summarized in Table [S1](#epi14934-sup-0002){ref-type="supplementary-material"}.

2.3. Gene expression profiling {#epi14934-sec-0010}
------------------------------

Ten milligrams of snap‐frozen human brain tissue was used for total RNA extraction using Trizol reagent (Thermo Fisher Scientific), followed by DNAse digestion. RNA quality was verified on the Shimadzu MultiNA capillary electrophoresis system (Shimadzu). Following Dynabead Oligo(dT) enrichment (Invitrogen), messenger RNA (mRNA) was prepared into sequence‐ready libraries with the NEBNext mRNA Library Prep Reagent Set for Illumina (New England Biolabs). Libraries were sequenced as described earlier with a 100 bp single‐read length. Sequence tags were aligned to the human reference genome hg19 and Ensembl transcript reference (*Homo Sapiens* 75) using STAR aligner.[21](#epi14934-bib-0021){ref-type="ref"} The numbers of read tags aligning to each region were extracted using featureCounts[20](#epi14934-bib-0020){ref-type="ref"} producing a matrix of counts (tags per gene per sample). Genes with fewer than 100 sequence reads across all samples were removed from further analysis.

2.4. Identification of confounding factors {#epi14934-sec-0011}
------------------------------------------

To estimate sequence abundance, we used generalized linear modeling (GLM) with a negative binomial link function implemented in the edgeR package.[22](#epi14934-bib-0022){ref-type="ref"} Read abundance values were normalized using trimmed mean of M values (TMM) normalization.[23](#epi14934-bib-0023){ref-type="ref"} Disease groups were modeled along with potential confounding factors of sex, age, and cell admixture. With regard to cellular composition of the tissue, we focused on normalizing for neuronal cell content, as this has been shown to strongly affect differential results and be a large source of unwanted variance.[24](#epi14934-bib-0024){ref-type="ref"}, [25](#epi14934-bib-0025){ref-type="ref"} To decide if the modeling method would successfully account for sources of uninformative variation, the GLM methylation model was fitted on neuronal nuclear antigen (NeuN) promoter methylation, whereas in the RNA set the expression of this gene was used. The rank of the resulting beta values was tested for an association with gene sets derived from previous experiments using a Wilcox gene set test (X Genes, genes located on the X chromosome; Y Genes, genes located on the Y chromosome; Horvath (up/down), genes identified as having methylation that is correlated or anticorrelated with age (derived from Horvath et al[26](#epi14934-bib-0026){ref-type="ref"}), and Neuron Marker, the top 500 neuron‐specific genes compared to astrocyte and endothelial cells (derived from Zhang et al[27](#epi14934-bib-0027){ref-type="ref"}). Notably, all major markers of sex, age, and neuron specificity behaved as expected (Figure [S1](#epi14934-sup-0001){ref-type="supplementary-material"}). The beta value for NeuN promoter methylation was correlated significantly with neuronal marker genes *P* \<1.2e‐5, indicating that the NeuN methylation beta values captured a significant amount of the neuron‐specific signature. For differential methylation analysis, pairwise comparisons between all diagnosis groups were performed (ie, CTRL; FCD Ia, IIa, and IIb; TLE), generating *P* values and log2‐fold changes used for filtering and downstream analysis. Group sizes of all subtype pathologies and controls were equally matched ranging from four to six samples per group with a mean of five samples per group.

2.5. Cluster analysis and genomic distribution of differentially methylated regions {#epi14934-sec-0012}
-----------------------------------------------------------------------------------

Clustering was performed by taking the library size normalized values for differential regions (*P* \< 1e‐4), which were unique to any pairwise comparison and had absolute log2‐fold change (FC) for confounding covariates of \<0.5. These values were scaled to the normal distribution before performing Manhattan distance‐based hierarchical clustering on both regions and samples using the heatmap.2 function in the R package gplots.

The circos plot was generated using circlize[28](#epi14934-bib-0028){ref-type="ref"} package. Methylated regions with *P* \< 1e‐4 for comparisons of epilepsy groups vs controls are shown. An equal number (958) of top‐enriched regions are shown for mRNA‐seq. Proportions for pie charts were calculated by assigning differentially methylated regions (DMRs) to exactly one feature.

Differentially methylated regions were assigned to the first features in the following priority: promoters, enhancers, and gene bodies. Any remaining DMRs were assigned as intergenic. When calculating the significance of the overlap of DMRs with genomic features, the Fisher\'s exact test was used with a random sample of 1000 regions of the same genomic width as the original set.

2.6. Correlation of DNA methylation and mRNA expression {#epi14934-sec-0013}
-------------------------------------------------------

To explore the relationship between DNA methylation and mRNA expression when comparing disease groups, the signed rank of the −log10 (*P* value) of the change in the promoter DNA methylation (within 2 kbp from TSS) was plotted vs the signed rank of the −log10 (*P* value) of the change in RNA transcription. This was transformed into a density distribution using a two‐dimensional kernel. This density distribution was then colored as a heatmap for visualization.

2.7. Gene panel sequencing {#epi14934-sec-0014}
--------------------------

Ten milligrams of snap‐frozen human brain tissue was used for genomic DNA extraction using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer\'s instructions. For panel sequencing, all exons and flanking intronic regions of target genes were captured using 200 ng of genomic DNA and the HaloPlex target enrichment system (Agilent Technologies), according to the manufacturer\'s protocol. Quality check was performed using the 2100 Bioanalyzer (Agilent Technologies). DNA libraries were sequenced on a Genome Analyzer IIx (GAIIx, Illumina) in 100 bp reads. Bioinformatics analysis was performed using BWA[17](#epi14934-bib-0017){ref-type="ref"} to map sequencing reads to the human reference genome UCSC GRCh37/hg19 assembly, Picard (V1.109, <http://broadinstitute.github.io/picard/>), GATK (V3.1, <https://www.broadinstitute.org/gatk/>) to call variants, and Annovar[29](#epi14934-bib-0029){ref-type="ref"} to perform variants annotation. All possible sequencing and alignment artifacts were excluded from further analysis. Upon their identification and validation through conventional Sanger sequencing, we classified variants in patients and controls according to the American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines.[30](#epi14934-bib-0030){ref-type="ref"} Genes included in the panel are summarized in Table [S2](#epi14934-sup-0002){ref-type="supplementary-material"}.

To validate *DEPDC5* gene expression from a newly identified likely pathogenic *DEPDC5* variant, we used custom‐designed primers mapping on DEP domain containing 5 (DEPDC5) exons 7 and 10. Following real‐time polymerase chain reaction (RT‐PCR) using fastStart Taq DNA Polymerase (Roche), RT‐PCR products were checked on 1% agarose gel (Experteam). DNA bands were excised, purified with the Nucleospin Extract II agarose gel extraction kit (Macherey‐Nagel), and sequenced afterward using BigDye Terminator V1.1 chemistry (Life Technologies). Primers and RT‐PCR conditions are available upon request.

2.8. Data access {#epi14934-sec-0015}
----------------

Methyl‐Seq and mRNA‐Seq data were deposited in the NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo>) and are available under GEO accession number [GSE128301](GSE128301).

3. RESULTS {#epi14934-sec-0016}
==========

Sequencing was used to assess mRNA expression and DNA methylation changes in 26 samples (Figure [1](#epi14934-fig-0001){ref-type="fig"}A‐B). The experimental design using methyl‐CpG and mRNA capture followed by massive parallel sequencing to characterize DNA methylation (Methyl‐Seq) and gene expression (mRNA‐Seq) patterns is shown in Figure [1](#epi14934-fig-0001){ref-type="fig"}C.

3.1. Multidimensional scaling of DNA methylation profiles and confounding factors {#epi14934-sec-0017}
---------------------------------------------------------------------------------

DNA methylation was detected in 505 Mbp of the human genome, and we assessed differential methylation in FCD subtypes, non‐FCD epilepsy (ie, TLE), and nonepilepsy age‐matched controls. Analysis of DNA methylation in clinical tissue samples may be subject to multiple confounding factors that are technical (eg, batch effects) or biological (eg, age) in origin. We adjusted for known confounders in our analysis by assessing sex,[31](#epi14934-bib-0031){ref-type="ref"} age,[32](#epi14934-bib-0032){ref-type="ref"} and heterogeneous cell composition[24](#epi14934-bib-0024){ref-type="ref"}, [33](#epi14934-bib-0033){ref-type="ref"} using generalized linear modeling (Figure [S1](#epi14934-sup-0001){ref-type="supplementary-material"}). DMRs associated with confounding variables (β \> 0.5) were removed, and a total of 1333 DMRs were identified at a threshold of *P* \<1e‐4 (Figure [2](#epi14934-fig-0002){ref-type="fig"}A, left panel). DMRs were categorized showing 675 regions with elevated (hyper‐) methylation and 658 regions with reduced (hypo) methylation. Multidimensional scaling (MDS) was used to identify patterns in DNA methylation by integrating phenotypic variables (age, sex, and cellular composition). This analysis was important because it allowed us to assess DNA methylation changes in sampled brain regions and tissue obtained from biopsy or autopsy. We observed no association for DMRs with anatomic lobe (Figure [2](#epi14934-fig-0002){ref-type="fig"}B), or sample origin (autopsy or biopsy; Figure [2](#epi14934-fig-0002){ref-type="fig"}C). However, we did observe DMR clustering by disease group (Figure [2](#epi14934-fig-0002){ref-type="fig"}D), which was not associated with copy number variation or genomic input (Figure [2](#epi14934-fig-0002){ref-type="fig"}E). Taken together, these results suggest that the DNA methylation differences identified between disease groups were unlikely to be a result of genetic background or phenotypic confounding variables.

![A, Genome‐wide sequencing data identified strong differences in DNA methylation but not messenger RNA (mRNA) expression in epilepsy subtypes compared to a nonepilepsy control group. Plots compare the sequence abundance (logCPM) and fold change (log2FC) for epilepsy subtypes (*P* \< 1e‐4, dark gray; *P* \> 1e‐4, light gray). The number of differentially methylated regions (DMRs) and differentially expressed genes (DEGs) is shown. (B‐E), Identified DMRs are associated with disease groups rather than covariates. A multidimensional scaling (MDS) plot was generated from DMRs (*P* \< 1e‐4) with low confounding variable influence (β \< 0.5). Samples were labeled with the covariates: (B) Lobe and (C) Sample source showed no association with the identified DMRs. D, Epilepsy subtypes and nonepilepsy control groups showed the strongest clustering. E, Input DNA (genetic background) did not drive clustering according to disease groups](EPI-60-1091-g002){#epi14934-fig-0002}

Multidimensional scaling analysis of differential gene expression data from the same samples identified "lobe" as strong additional phenotypic variable (Figure [S2](#epi14934-sup-0001){ref-type="supplementary-material"}). Adjusted mRNA comparisons of FCD and non‐FCD epilepsy groups with the nonepilepsy control group identified 10 differentially expressed genes (DEGs; six increased and four decreased) at a threshold of *P* \< 1e‐4 (Figure [2](#epi14934-fig-0002){ref-type="fig"}A, right panel). When compared to methylation sequencing results, mRNA had a much higher variance, with a median excess dispersion of 0.159 (compared to 0.008 for Methyl‐Seq). The results imply that because of variance, gene expression was less reliable for FCD classification.

3.2. Differential hierarchical cluster analysis {#epi14934-sec-0018}
-----------------------------------------------

To determine whether genomic DNA methylation can be used to identify FCD subtypes we applied differential hierarchical cluster analysis. Intergroup comparisons showed that FCD subtypes were distinguishable by DNA methylation highlighting separation of FCD groups from other epilepsy phenotypes (TLE), and no‐seizure controls (Figure [3](#epi14934-fig-0003){ref-type="fig"}A). To define methylation with genomic location, we assigned DMRs with promoter (±2 kb from TSS), gene body, or enhancer sequences of annotated genes. From the total of 1333 DMRs, 465 were successfully annotated with one of these features. Promoters represented only 12% of all the differential methylation, whereas gene bodies and intergenic regions accounted for the majority of the changes (29% and 30%, respectively). Among the top associations of differentially methylated genes (DMGs), calcium/calmodulin‐dependent protein kinase 1D (*CAMKD1*) was increased for methylation in FCD type Ia. In contrast, alpha‐internexin (*INA*) was decreased for methylation in FCD type IIa compared to non‐FCD epilepsy. Other DMGs appeared highly specific for FCD type IIb or TLE (Figure [3](#epi14934-fig-0003){ref-type="fig"}B). Our data support the concept of using DNA methylation signatures as diagnostic biomarkers to support classification of, for example, FCD subtypes in clinical praxis.

![A, Differentially methylated regions (DMRs) distinguished focal cortical dysplasia (FCD) Ia, FCD IIa, FCD IIb, temporal lobe epilepsy (TLE), and nonepilepsy control from each other in differential cluster analyses. Heatmaps of DMRs (*P* \< 1e‐4) with low confounding variable influence (β \< 0.5) are shown. The numbers of DMRs for each comparison are displayed next to each heatmap. B, Examples of differentially methylated genes (DMGs), which were identified through DMRs that are located at a gene\'s promoter, gene body, or enhancer. Genome, annotated part of the genome; Location, position of DMG on the hg19 human reference genome; log10P, the highest log10 *P* value for the DMG; Gene, annotated gene name; methylation intensity, scaled sequence abundance, showing comparisons with cutoff of *P* \< 1e‐4; RPM, reads per million](EPI-60-1091-g003){#epi14934-fig-0003}

3.3. Genomic distribution of DMRs and correlation with gene expression {#epi14934-sec-0019}
----------------------------------------------------------------------

Genome‐wide visualization of all differential methylation signals demonstrated even distribution on all autosomes, with no evidence for clustering at particular chromosomes or gross chromosomal regions (eg, toward central autosome domains or ends; Figure [4](#epi14934-fig-0004){ref-type="fig"}A). DMRs were observed at genomic features such as gene promoters (±2 kb from TSS), exons, introns, enhancers, and CpG islands (CGIs) together with their shores (±1 kb from CGIs) and shelves (±1‐9 kb from CGIs; Figure [4](#epi14934-fig-0004){ref-type="fig"}B). Promoters represented only 12% of all the differential methylation, whereas gene bodies and intergenic regions accounted for the majority of the changes (29% and 30%, respectively). Differential methylation at CGIs, shores, and shelves accounted for \<22% of total DMRs, with the majority observed in CpG shelves (Figure [4](#epi14934-fig-0004){ref-type="fig"}C).

![A, Whole genome sequencing detected strong changes in DNA methylation and messenger RNA (mRNA) expression that distinguished epilepsy subtypes. Differential regions are shown on the human genome autosomes. The outer subtype ring summarizes hypermethylation (cyan) and hypomethylation events (red) in the individual epilepsy groups, that is, focal cortical dysplasia (FCD) Ia, FCD IIa, FCD IIb, and temporal lobe epilepsy (TLE), compared to the nonepilepsy control group showing 958 unique loci with a cutoff of *P* \< 1e‐4. The inner subtype ring summarizes mRNA changes in the epilepsy groups compared to the nonepilepsy control group. Genomic locations of differentially methylated regions (DMRs) and differentially methylated genes (DMG)s are shown. Heatmap scale shows differential methylation and expression changes between epilepsy and nonepilepsy groups expressed as the --log10 *P* value. The outer circle of genes is the top 30 DMG. B, Graphical representation of genomic features and CpG Islands, shelves, and shores. Regions are: promoter (±2 kb from TSS), gene body, CpG islands (CGIs), and CpG island shores (±1 kb from CGI) and shelves (±1‐9 kb from CGI). C, The majority of subtype DMRs were colocated with functional genomic elements. Distribution of identified DMRs clustered across genomic features including gene promoter region, gene bodies, CGIs and CGI shores and shelves. D, Rank‐rank density plot showing significant inverse correlation of DNA promoter methylation and gene expression in all subtype pathologies. Hypermethylation was associated with reduced gene expression (upper left corner), whereas hypomethylation was primarily found in upregulated genes (lower right corner)](EPI-60-1091-g004){#epi14934-fig-0004}

Because DNA methylation may functionally regulate gene expression, we assessed whether pathology‐specific DMRs from Methyl‐Seq were associated with gene expression changes from mRNA‐Seq. Comparing ranked differentials we observed an inverse correlation for promoter methylation with gene expression in all subtype pathologies, that is, hypermethylation was associated with reduced gene expression, whereas hypomethylation was found primarily in upregulated genes (Spearman correlation, *p* ~TLE~ = 2.3e‐15, *p* ~FCD_Ia~ = 3.2e‐05, *p* ~FCD_IIa~ = 1.1e‐77, *p* ~FCD_IIb~ = 9.6e‐38; Figure [4](#epi14934-fig-0004){ref-type="fig"}D).

3.4. Mechanistic target of rapamycin pathway analysis {#epi14934-sec-0020}
-----------------------------------------------------

We next specifically explored the possibility of molecular alterations in the mechanistic target of rapamycin (mTOR) pathway, because mutations in genes associated with mTOR were described recently with the pathogenesis of FCD II subtypes.[34](#epi14934-bib-0034){ref-type="ref"}, [35](#epi14934-bib-0035){ref-type="ref"}, [36](#epi14934-bib-0036){ref-type="ref"} To understand the possible genetic burden in our cohort, we performed panel sequencing of 54 mTOR pathway--related genes. We obtained a mean coverage ranging from 76× to 1539x. Tissue DNA from a patient histopathologically classified as FCD IIa carried a novel, likely germline, and likely pathogenic variant affecting the donor splice site of *DEPDC5* exon 8 (DEP Domain Containing 5; [NM_001242896.1](NM_005163)): c.483 + 1G\>A, nine reference reads and 20 alternative reads (heterozygous at Sanger sequencing; Figure [1](#epi14934-fig-0001){ref-type="fig"}A). In silico analysis for the mutation predicted a frame shift with the insertion of a premature stop codon. If translated, the truncated protein is predicted to contain 153 instead of 1603 amino acids (Figure [S3](#epi14934-sup-0001){ref-type="supplementary-material"}). To demonstrate that the identified variant affected mRNA splicing, we amplified cDNA synthetized from mRNA extracted from the dysplastic brain tissue and blood of that patient using primers mapping on *DEPDC5* exons 7 and 10. Agarose gel electrophoresis revealed two RT‐PCR products in both tissues, and Sanger sequencing confirmed that exon 8 was deleted (Figure [S3](#epi14934-sup-0001){ref-type="supplementary-material"}). Due to our retrospective study design, we had no access to parents' blood to verify whether this constitutive mutation occurred de novo. Another patient, also classified with FCD IIa, carried a missense variant of uncertain significance in *AKT1* exon 11 (AKT serine/threonine kinase 1; [NM_005163](NM_005163)): c.1099C\>T; p.Arg367Cys, 576 reference reads and 475 alternative reads (heterozygous at Sanger sequencing), frequency in gnomAD database =0.00001625, one occurrence in the Catalogue of Somatic Mutations in Cancer = COSM1235769 in brain tissue (Figure [1](#epi14934-fig-0001){ref-type="fig"}A). No blood sample of that patient was available for further genetic studies. In the control group, we identified variants in the following genes: *MTOR* ([NM_004958.3](NM_004958)): c.3113T\>C; p.Met1038Thr, 1076 reference reads, 717 alternative reads (heterozygous at Sanger sequencing), not reported in literature or in public databases; *TSC2* (tuberous sclerosis complex 2; [NM_000548.3](NM_000548)): c.4524_4526delCTT; p.1508_1509del, 2043 reference reads, 1656 alternative reads (heterozygous at Sanger sequencing), frequency in gnomAD databases = 0.005092; *DEPDC5* ([NM_001242896.1](NM_005163)): c.4510 C\>T; p.His1504Tyr, 3308 reference reads, 1414 alternative reads (heterozygous at Sanger sequencing), not reported in literature or in public databases. These variants were considered of uncertain significance as they were either absent or present with low frequency (\<1%) in public databases and have not been associated previously with human disease. Furthermore, in silico pathogenicity prediction results were inconclusive, segregation studies were not possible in the families, and none of the control cases exhibited seizures at any point before death/sampling. Activation of mTOR signaling has been postulated in FCD II,[37](#epi14934-bib-0037){ref-type="ref"} but analysis of mRNA profiling data for our panel of mTOR pathway--related genes did not identify changes in gene expression. However, we found seven genes (*FOXO6, GNAQ, PHLPP1, PDPK1, TSC2, DEPDC5*, and *CNTNAP2*) to be differentially methylated either in their promoter region or gene body (Table [1](#epi14934-tbl-0001){ref-type="table"}, Figure [S4](#epi14934-sup-0001){ref-type="supplementary-material"}). Notably, PHLPP1 gene body and FOXO6 promoter hypermethylation distinguished FCDs from TLE and nonepilepsy controls, but we did not observe differential methylation of mTOR pathway--related genes in FCD subtypes. Taken together, our data provided no evidence that genes implicated in the mTOR pathway could be used as molecular classifiers to distinguish FCD subtypes.

###### 

Top 10 differentially promoter or gene body methylated mTOR pathway--related genes

  DataSet          GeneID                  logFC   *P* value          Adj. *P* value   Contrast          GeneSymbol
  ---------------- ----------------------- ------- ------------------ ---------------- ----------------- ---------------
  Promoter         ENSG00000204060         1.75    **1**.**61E‐05**   0.05176          Ctrl_vs_FCDIIa    ***FOXO6***
  Promoter         ENSG00000156052         1.13    **4**.**17E‐05**   0.03882          Ctrl_vs_FCDIIb    ***GNAQ***
  Promoter         ENSG00000204060         1.82    **9**.**97E‐05**   0.04797          Ctrl_vs_FCDIIb    ***FOXO6***
  Promoter         ENSG00000132024         −0.26   0.00014            0.07459          Ctrl_vs_FCDIa     *CC2D1A*
  Promoter         ENSG00000204060         1.54    0.00033            0.10911          Ctrl_vs_FCDIa     *FOXO6*
  Promoter         ENSG00000118689         0.72    0.00069            0.13200          Ctrl_vs_FCDIa     *FOXO3*
  Promoter         ENSG00000167965         −0.32   0.00140            0.52418          FCDIa_vs_FCDIIb   *MLST8*
  Promoter         ENSG00000164327         0.37    0.00211            0.14265          Ctrl_vs_FCDIIb    *RICTOR*
  Promoter         ENSG00000040199         −0.24   0.00310            0.16109          Ctrl_vs_FCDIIb    *PHLPP2*
  Promoter         ENSG00000100150         0.28    0.00480            0.58119          FCDIIb_vs_TLE     *DEPDC5*
  Genomic region                                                                                         
  GeneBody         18:60629433‐60629997    1.16    **3**.**54E‐07**   0.06283          Ctrl_vs_FCDIa     ***PHLPP1***
  GeneBody         18:60629433‐60629997    0.97    **2**.**62E‐05**   0.21187          Ctrl_vs_FCDIIb    ***PHLPP1***
  GeneBody         16:2629631‐2630231      −1.11   **2**.**70E‐05**   0.26838          Ctrl_vs_TLE       ***PDPK1***
  GeneBody         16:2110009‐2110609      0.63    **2**.**81E‐05**   0.23720          FCDIa_vs_FCDIIb   ***TSC2***
  GeneBody         22:32220413‐32221013    1.32    **5**.**38E‐05**   0.37167          FCDIIb_vs_TLE     ***DEPDC5***
  GeneBody         18:60629433‐60629997    0.82    **6**.**32E‐05**   0.41850          Ctrl_vs_FCDIIa    ***PHLPP1***
  GeneBody         22:32220413‐32221013    1.12    **7**.**01E‐05**   0.55320          FCDIIa_vs_TLE     ***DEPDC5***
  GeneBody         7:146547868‐146548468   −1.11   **8**.**22E‐05**   0.55320          FCDIIa_vs_TLE     ***CNTNAP2***
  GeneBody         17:78698196‐78698796    −0.74   0.00017            0.40836          Ctrl_vs_TLE       *RPTOR*
  GeneBody         22:32220413‐32221013    −0.90   0.00017            0.34157          Ctrl_vs_FCDIIb    *DEPDC5*

Table summarizes differential methylation of mTOR pathway--related genes. Differentials meeting our significance criteria (*P* \< 1e‐4) were marked in bold.

Abbreviations: Ctrl, control; FCD, focal cortical dysplasia; TLE, temporal lobe epilepsy; logFC, log2‐fold change; *CNTNAP2,* contactin‐associated protein‐like 2; *DEPDC5,* DEP domain containing 5; *FOXO6*, forkhead box O6; *GNAQ*, G protein subunit alpha Q; *PHLPP1,* ph domain and leucine rich repeat protein phosphatase 1; *PDPK1,* 3‐phosphoinositide dependent protein kinase 1; *TSC2,* tuberous sclerosis complex 2.
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4. DISCUSSION {#epi14934-sec-0021}
=============

Hierarchical cluster analysis identified disease‐specifying DNA methylation signatures in three common FCD subtypes, that is, FCD Ia, IIa, and IIb. This study is first of its kind showing that human FCD subtypes can be distinguished based on DNA methylation. Methylation sequencing in FCDs showed intergenic regions, gene bodies, and enhancers to be subject to differential methylation, which seemed to be distinct from promoter‐centered DNA methylation changes described in human brain tumors.[12](#epi14934-bib-0012){ref-type="ref"} These findings have implications for the understanding and scientific approach to FCD classification and may pave the way toward an integrated clinicopathologic and molecular diagnosis of focal epilepsies.

FCD IIa and IIb are the most common malformations of cortical development in children with drug‐resistant focal epilepsy.[1](#epi14934-bib-0001){ref-type="ref"} Despite the growing body of studies addressing FCD, with more than 740 papers listed in PubMed since the release of the first international consensus classification in 2011, consistent information about their origin or timing of the lesion during brain development is still lacking.[38](#epi14934-bib-0038){ref-type="ref"}, [39](#epi14934-bib-0039){ref-type="ref"} Somatic mutations in genes belonging to the mTOR pathway have been shown to occur in the range of 15.6% to 46% of patients with FCD according to different studies.[34](#epi14934-bib-0034){ref-type="ref"}, [36](#epi14934-bib-0036){ref-type="ref"}, [38](#epi14934-bib-0038){ref-type="ref"}, [40](#epi14934-bib-0040){ref-type="ref"}, [41](#epi14934-bib-0041){ref-type="ref"}, [42](#epi14934-bib-0042){ref-type="ref"}, [43](#epi14934-bib-0043){ref-type="ref"} The genetic variants represent somatic mosaicisms, affecting predominantly *MTOR* or *DEPDC5*, with allele fractions of 1%‐12.6 %. We identified variants in mTOR pathway genes in 2 of 15 patients with FCD (14.2%) including a novel likely pathogenic germline splicing variant in *DEPDC5* and a single nucleotide variant of uncertain significance in *AKT1*. The sequencing coverage of 76× to 1539× may have been too low to identify somatic mutations with low mutant allele fraction in the other FCD samples. Of interest, our DNA methylation and RNA sequencing analysis did not reveal the mTOR pathway as a principal target. The large gap of noninformative genetic data in approximately 60%‐80% of patients with FCD II, in particular those with FCD IIb, calls for extended molecular‐genetic investigations integrating single‐cell genome‐wide DNA[38](#epi14934-bib-0038){ref-type="ref"} and RNA sequencing[44](#epi14934-bib-0044){ref-type="ref"} or alternative sequencing strategies[45](#epi14934-bib-0045){ref-type="ref"}, [46](#epi14934-bib-0046){ref-type="ref"} to potentially identify the pathogenic cause of FCD II. Future progress in precision medicine will build on such analysis to develop a targeted drug treatment, in particular when epilepsy surgery is not an option for a given patient. With increasingly available pharmacological compounds regulating the epigenomic machinery,[47](#epi14934-bib-0047){ref-type="ref"} our findings will add to the knowledge pool for searching these new drug targets.

Clinicopathologic classification of non--FCD‐II subtypes remains a matter of debate.[48](#epi14934-bib-0048){ref-type="ref"} Lesions in this category are histopathologically described by dyslamination and disrupted organization of cortical architecture, but with normal neurons and glial cells.[4](#epi14934-bib-0004){ref-type="ref"} MRI often shows no changes in signal intensity. Hence, these epilepsies are often regarded as "nonlesional." An inherent example is that of FCD type Ia, histopathologically defined by excessive microcolumns that are visible in some amount also in normal brain.[49](#epi14934-bib-0049){ref-type="ref"} Despite the severe clinical phenotype in children with neurodevelopmental delay, daily seizures and drug‐resistance from onset, an MRI specific signature and biomarker of FCD Ia, has not been established.[4](#epi14934-bib-0004){ref-type="ref"} In addition, published clinicopathologic series of this subtype are limited.[48](#epi14934-bib-0048){ref-type="ref"} Our methylation data, although highly limited with regard to sample numbers, suggests FCD Ia to be a distinct molecular entity, which may be highly relevant with regard to the development of an integrated clinicopathologic and genetic classification of FCD.

Our protocol distinguished the most common FCD I and II subtypes, that is, FCD Ia, IIa, and IIb, from each other, but also from epileptogenic neocortex without architectural abnormalities obtained from patients with chronic temporal lobe seizures as well as from nonepileptic neocortex obtained from postmortem and biopsy controls. This is an additional important finding of our study and in line with previously published data showing that methylation patterns in various epilepsy animal models associate with seizure phenotype and etiology.[15](#epi14934-bib-0015){ref-type="ref"}, [16](#epi14934-bib-0016){ref-type="ref"} However, the functional role of aberrant DNA methylation in the development of FCD will require further investigation.

Tissue heterogeneity is an important confounding factor in this type of study. Different ratios of cell types may contribute to variable molecular signatures of complex brain tissue samples.[25](#epi14934-bib-0025){ref-type="ref"} In this study, we used state of the art statistical methods to correct for cellular heterogeneity--based DNA methylation. Wilcox gene set testing and multidimensional scaling analysis showed that neuronal methylation was not the primary driver of FCD subtype clustering. Future studies will need to dissect the methylation profiles of all major cell types contributing to the epileptic network in FCD.

In conclusion, a comprehensive approach integrating genotype‐phenotype analysis will be key to better understand FCD pathogenesis and classify clinically meaningful FCD subtypes. Despite the tremendous advances in genetic mapping used by many groups and consortia, it seems that genetic factors alone cannot fully explain FCD susceptibility. Our data for the first time suggest that DNA methylation signatures may help to classify FCD subtypes. Further studies are needed to validate the present findings and further address the large spectrum of histopathologically described FCD variants and hitherto unclassifiable specimens clinically suspected as FCD (which was beyond the purpose of this study). Characterizing the methylome in epilepsy tissue will also add to the growing demand for targeted pharmacologic treatment, which is needed urgently for approximately 17 million people with therapy‐resistant epilepsy worldwide.[50](#epi14934-bib-0050){ref-type="ref"} The results of this study strengthen the evidence base against DNA methylation merely being an epiphenomenon of FCD development.
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